Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Diabetes is a major public health problem that is moving toward epidemic proportions comprehensively. Around the world, the predominance of chronic, non-communicable diseases is expanding at an alarming rate. Confusions from Diabetes, for example, coronary corridor and fringe vascular malady, stroke, diabetic neuropathy, removals, renal disappointment, and visual deficiency are bringing about expanding inability, diminished future and tremendous wellbeing costs for essentially every general public. Diabetes is sure to be a standout amongst the most difficult medical issues in the 21st century. In this session, we are focusing on the complexity of Diabetes.

  • Track 1-1Type 1 Diabetes
  • Track 1-2Type 2 Diabetes
  • Track 1-3Nerve Disease
  • Track 1-4Kidney disease
  • Track 1-5Oral Complications
  • Track 1-6Steroid diabetes

 

Diabetes mellitus is a heterogeneous group of disorders described by persistent hyperglycemia. Type 1 and type 2 both are caused by a combination of genetic and environmental risk factors. In any case, there are other rare forms of diabetes that are directly inherited. These include maturity-onset diabetes and diabetes because of mutations in mitochondrial DNA. Within the following decade, the qualities that the genes that increase the risk of developing all forms of diabetes will likely be known. It is, in this way, important that researchers, wellbeing experts, health professionals, and members of the population at large consider how to maximize the advantages, and minimize the disadvantages of predictive genetic testing for diabetes.

  • Track 2-1Genetics of metabolic syndrome
  • Track 2-2Role of genetics in type 2 diabetes
  • Track 2-3Genes responsible for type 2 diabetes
  • Track 2-4Mechanism and Variants of diabetes gene
  • Track 2-5X-linked neonatal diabetes mellitus
  • Track 2-6Genetic Mutation

 

Nutrition and physical activity are essential parts of a healthy lifestyle when we have diabetes. Some foods raise blood glucose more than others. To deal with our blood glucose, we need to balance what we eat and drink with physical activity and diabetes medicine if we take any. In recent years, there has been much new proof evidence demonstrating the potentially preventable nature of type 2 diabetes, especially by the implementation of lifestyle measures such as weight control and exercise. In perspective on this and the devastating health impact of the disease, it seems prudent that primary prevention should be a major priority. This session, concentrating on nutritional intervention in the prevention of type 2 diabetes is used to make disease-specific recommendations.

  • Track 3-1Medical nutrition therapy
  • Track 3-2Balanced diet index
  • Track 3-3Low glycaemic index diet
  • Track 3-4Ketogenic Diet for Diabetes
  • Track 3-5Meal replacement diet plans
  • Track 3-6Poultry Nutrition

The objectives of this session are to reduce morbidity and to prevent complications. Medications that reduce insulin resistance include thiazolidinedione and biguanides, which have anti-hyperglycemic effects and insulin-sensitizing. Vast amounts of insulin are additionally utilized in overcoming insulin resistance. Reaction to the normal dose of insulin is seen in occurrences in which the resistance is due to enhanced destruction at the subcutaneous injection site. Antiobesity drugs, for example, orlistat, may reduce insulin resistance and related cardiovascular risk factors through weight reduction and other mechanisms.

  • Track 4-1Insulin Medication of Type 2 Diabetes Mellitus
  • Track 4-2Insulin Therapy
  • Track 4-3Insulin with Oral Medications
  • Track 4-4Types of insulin treat diabetes
  • Track 4-5Postprandial Hyperglycemia

 

Diabetes can affect all aspects of the body, including the skin. Actually, such issues are sometimes the first sign that a person has diabetes.  A variety of dermatologic indications have been connected with diabetes mellitus; these conditions fluctuate in seriousness and can be benign, deforming, and even life-threatening. Such skin changes can insight into patients’ glycemic control and might be the first sign of metabolic derangement in undiagnosed patients with diabetes. Recognition and management of these conditions are imperative in maximizing the quality of life and in avoiding serious adverse effects in patients with diabetes.

  • Track 5-1Necrobiosis Lipoidica
  • Track 5-2Acanthosis Nigricans
  • Track 5-3Cutaneous Infections associated with DM
  • Track 5-4Granuloma Annulare
  • Track 5-5Diabetic Bullae
  • Track 5-6Diabetic Dermopathy (shin spots)

Obesity is the main source of preventable disease and passing in the world. In recent years, the number of overweight people in industrialized countries has expanded, altogether, to such an extent that the World Health Organization (WHO) has considered obesity an epidemic. In the United States, 69% of the grown-up populace is overweight or obese. In Canada, the self-reported data demonstrate that 20% of men and 17% of women are obese and 40% of men and 27% of women are overweight. People who are obese are at a lot higher hazard for serious medical conditions, for example, heart attack, high blood pressure, stroke, diabetes, gallbladder disease, and different cancers than people who have a healthy weight.

  • Track 6-1Lipid and Glucose Metabolism
  • Track 6-2Obesity in pregnancy
  • Track 6-3Etiology of obesity
  • Track 6-4Proteins and micronutrients
  • Track 6-5Surgical management of obesity
  • Track 6-6Weight Management

Due to the peripheral nerve dysfunction related to diabetes (diabetic neuropathy), patients have a reduced ability to feel torment. This implies minor wounds may remain undiscovered for quite a while. People with diabetes are likewise in danger of developing a diabetic foot ulcer. The research assesses that the lifetime occurrence of foot ulcers inside the diabetic community is around 15% and may move toward becoming as high as 25%. Those few patients are then 50% more likely to undergo another lower limb amputation. As such, diabetic foot care is one of the most essential parts of diabetes management and so we included this session at this wonderful gathering to discuss.

  • Track 7-1Diabetic foot Ulcer
  • Track 7-2Diabetic foot pathophysiology
  • Track 7-3Diabetic Charcot Neuropathy
  • Track 7-4Diabetic Foot and Ankle

Diabetes mellitus aggravates mechanisms underlying atherosclerosis and heart failure. Unfortunately, these mechanisms are not sufficiently modulated by therapeutic strategies focusing solely on optimal glycemic control with currently accessible drugs or approaches. Women with diabetes have a considerably more serious danger of coronary illness compared to those of similar age who don't have diabetes. Actually, cardiovascular disease is by a long shot the most frequent reason for death in the two people with diabetes. Lamentably, in patients with diabetes, improvement in survival after a heart attack has been not exactly half as much as in the overall population. The main objective of this conference is to build open attention to early discovery and better treatment of diabetes to prevent its complications.

  • Track 8-1Heart disease
  • Track 8-2Stroke
  • Track 8-3High Blood Pressure
  • Track 8-4Diagnosis methods of Heart Disease
  • Track 8-5Atherosclerosis
  • Track 8-6Hypertension

 

People with diabetes are at higher risk for some, but not all, forms of cancer. The relationship between the two diseases is complex and surrounded by unanswered questions. Diabetes is associated with increased risk for some cancers (liver, pancreas, endometrium, colon and rectum, breast, bladder). Diabetes is associated with a reduced risk of prostate cancer. For some other cancer sites, there appears to be no association or the evidence is inconclusive. We hope this session to address some important questions about the meaningful association between diabetes and cancer incidence or prognosis.

  • Track 9-1Colon cancers
  • Track 9-2Kidney cancers
  • Track 9-3Endometrial cancers
  • Track 9-4Insulin secretagogues
  • Track 9-5Thiazolidinediones

 

Biomarkers have an imperative impact in leading clinical trials and treating patients. Advances in molecular diagnostics help restorative experts make proficient, scientifically valid decisions. All the more efficient discovery and utilization of biomarkers in the development of anti-diabetes drugs will rely on accelerating our understanding of the pathogenesis of diabetes and explicitly its macrovascular complications. Procedural enhancements from different fields, particularly disease, are starting to demonstrate the route towards better models of diabetes pathogenesis and molecular biomarker discovery.

  • Track 10-1Serum biomarkers for diabetes
  • Track 10-2Carbonyl stress
  • Track 10-3Pulse wave analysis
  • Track 10-4Auto fluorescence
  • Track 10-5Biomarkers of vascular function in diabetes
  • Track 10-6Salivary biomarkers for diabetes
  • Track 10-7Novel biomarkers for diabetes

 

Our chances of developing type 2 diabetes depend on a combination of risk factors such as our genes and lifestyle. Although we can’t change risk factors such as family history, age, or ethnicity, we can change lifestyle risk factors around eating, physical activity, and weight. These lifestyle changes can affect our chances of developing type 2 diabetes

  • Track 11-1Diabetic Retinopathy
  • Track 11-2Prediabetes
  • Track 11-3Unexplained weight loss
  • Track 11-4Slow-healing sores
  • Track 11-5Thrush

 

Stem cell therapy holds immense guarantee for the treatment of patients with diabetes mellitus. Research on the capacity of human embryonic stem cells to separate into islet cells has characterized the developmental stages and translation factors associated with this procedure. As a result, alternative forms of stem cell therapies, for example, umbilical cord stem cells, induced pluripotent stem cells and bone marrow-derived mesenchymal stem cells, have turned into an area of serious study. Recent advances in stem cell therapy may transform this into a realistic treatment for diabetes in the near future.

  • Track 12-1Islet cell transplantation
  • Track 12-2Mesenchymal stem cell therapy
  • Track 12-3Umbilical Stem Cells
  • Track 12-4Embryonic Stem Cell Research
  • Track 12-5Type 1 Diabetes Beta Cells

The thyroid organ is prone to several very distinct problems, some of which are very common These issues can be separated into [1]  the formation of nodules or lumps within the thyroid which are worrisome for the presence of thyroid cancer, [2] those concerning the production of hormone (too much, or too little) [3] those due to increased growth of the thyroid, causing compression of important neck structures or simply appearing as a mass in the neck, [4] those which are cancerous. Since the principle motivation behind thyroid hormone is to "run the body's metabolism," it is justifiable that individuals with this condition will have indications related to slow metabolism.

  • Track 13-1Thyroid and thymus
  • Track 13-2Role of the thyroid gland
  • Track 13-3Hypothyroidism
  • Track 13-4Hyperthyroidism

 

Nanotechnology in diabetes investigate has encouraged the advancement of novel glucose estimation and insulin delivery modalities which hold the possibility to drastically improve quality of life for diabetics. Current advancement in the field of diabetes explore at its interface with nanotechnology is our centre of attention. Specifically, we look at glucose sensors with nanoscale components including metal nanoparticles and carbon nanostructures. A portion of the applications of nanotechnology in treating diabetes mellitus are artificial pancreas, rather than pancreas transplantation utilization of artificial beta cells, for the oral conveyance of insulin use of nanospheres as biodegradable polymeric carriers and so on. In this session, the utilization of nanotechnology in treating diabetes mellitus will be discussing.

  • Track 14-1Nano Medicine
  • Track 14-2Artificial Pancreas
  • Track 14-3Monitoring Glucose levels
  • Track 14-4Nanoporous immunoisolation devices
  • Track 14-5Applications of Nanotechnology for Diabetes Management

 

There are heaps of chemical agents accessible to control and to treat diabetic patients, yet all-out recovery from diabetes has not been reported for up to this date. An alternative to these manufactured operators, synthetic agents, plants provides potential sources of hypoglycemic drugs are generally utilized in several traditional systems of medicine to prevent diabetes. A few medicinal plants have been researched for their medicinal use in various types of diabetes and have shown up in various scientific journals. The impacts of these plants may delay the advancement of diabetic difficulties and correct the metabolic irregularities using an abnormality using a variety of mechanisms. An impressive number of plants were exposed to clinical trials and were discovered effective. In addition, during the past few years, numerous phytoconstituents in charge of antidiabetic impacts have been separated from hypoglycaemic plants.

  • Track 15-1Herbs and Supplements
  • Track 15-2Herbal Metformin
  • Track 15-3Traditional Chinese medicine
  • Track 15-4Anti-diabetes plants

 

The endocrine issue is consistently astounding, including a mixed picture of hyposecretion and hypersecretion because of the information parts related to the endocrine system. For example, most kinds of hyperthyroidism are connected with an excess of thyroid hormone and a low dimension of thyroid animating hormone. Patients with multi-transfused thalassemia major may make serious endocrine complexities because of iron overload. Syndrome X is a term that is much of the time associated with the dissipates that exist together in various people with different sorts of cardiovascular disease (CVD) and furthermore diabetes in association with insulin resistance, hyperinsulinemia and cell ionic abnormality. 

  • Track 16-1Environmental Endocrinology
  • Track 16-2Neuro Endocrinology
  • Track 16-3Metabolic disorders
  • Track 16-4Symptoms and Diagnosis
  • Track 16-5Management of Metabolic syndrome

 

Type 1 diabetes is a constant disease described by the body's inability to produce insulin because of the auto-immune system demolition of the beta cells in the pancreas. Most pediatric patients with diabetes have type 1 and a lifetime reliance on exogenous insulin. This observable underneath portrays the impacts of insulin lack. Dietary nutrient D supplementation is related to reduce the danger of type 1 diabetes. Ensuring sufficient nutrient D supplementation for infants could turn around the trend in the incidence of type 1 diabetes. The goal of this session in type 1 diabetes is to avoid the acute and chronic complications of the disease.

  • Track 17-1Pediatric Endocrinology
  • Track 17-2Pediatric Diabetes
  • Track 17-3Pediatric Obesity
  • Track 17-4Pediatric Nursing
  • Track 17-5Pediatric Genetics

Diabetes type 1 and type  2 ought to be considered in the differential diagnosis of menstrual abnormalities and infertility. Reproductive period of diabetic ladies might be decreased because of delayed menarche and premature menopause.  During the reproductive years, diabetes has been related to menstrual abnormalities, for example, secondary amenorrhea and oligomenorrhea. Ladies with persistent menstrual abnormalities in spite of sufficient treatment need to be approached by broader evaluation, which will incorporate the examination of the hypothalamic– pituitary– ovarian axis and the hormonal status, anti-ovarian autoantibodies, presence of autoimmune thyroid disease and hyperandrogenism.

  • Track 18-1In vitro fertilization
  • Track 18-2Fertility preservation
  • Track 18-3Polycystic ovarian syndrome
  • Track 18-4Ovarian cysts
  • Track 18-5Pelvic mass and adhesions

 

The central neuroendocrine systems serve in as an interface between the brain and a significant number of the peripheral endocrine systems. A neuroendocrine system can be characterized as the glands and non-endocrine tissues, arrangements neurons and hormones, the neurochemicals and humoral signs they produce and receive, that work in a coordinated manner to collectively regulate a physiological or behavioural state. In this session, we define and describe different types of neuroendocrine systems, and review the basic integrative mechanisms that each people to operate under normal physiological circumstances.

  • Track 19-1Homeostasis
  • Track 19-2Growth Hormone
  • Track 19-3Obstructive Sleep Apnea Risk
  • Track 19-4Neuro inflammation
  • Track 19-5Neuroendocrine cancer
  • Track 19-6Pituitary

 

Contribution from continuous glucose monitors (CGMs) is a basic component of artificial pancreas (AP) frameworks, however, CGM execution issues keep on restricting advancement in AP research. While G4 PLATINUM has been incorporated into AP frameworks around the globe and used in numerous successful AP controller possibility studies, this system was intended to address the needs of overall CGM users as an adjunctive use system. This session explicitly addresses the heightened performance requirements for future AP studies.

  • Track 20-1New Therapeutic Mechanisms for Diabetes
  • Track 20-2New Discovery and Treatment for Type 2 Diabetes
  • Track 20-3Exploring novel therapies in diabetes treatment
  • Track 20-4Integrative gaming
  • Track 20-5CGM

 

Diabetes is a global disease. The field of diabetes innovation to advance and in order for diabetes products containing novel advancements to be developed and used, these items will need to survive economically. Financial conditions and approaches of national different administrative bodies that control access to therapeutic advances must be positive in order for a patient in that country to have access to technology, and these arrangements are frequently extraordinary in every nation. Approximately 250 million people affected by diabetes around the world, diabetes is extracting an expanding toll from the world economy. People with diabetes acquire medical costs that are a few times higher than those without diabetes. Moreover, diabetes prompts critical aberrant expenses to the economy through early retirement and a disproportionate requirement for sick days and disability. As the U.S. populace becomes more established and fatter, it may be foreseen that diabetes predominance rates and future expenses of this sickness may develop at much quicker rates than would be extrapolated from current prevalence rates.

  • Track 21-1Innovation in Diabetes products
  • Track 21-2RAGE
  • Track 21-3Economic of drug delivery
  • Track 21-4Market analysis of Diabetes products